These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 35834493)
41. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Novembrino C; Boscolo Anzoletti M; Mancuso ME; Shinohara S; Peyvandi F Haemophilia; 2019 May; 25(3):521-526. PubMed ID: 31044485 [TBL] [Abstract][Full Text] [Related]
42. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Carcao M; Mancuso ME; Young G; Jiménez-Yuste V Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681 [No Abstract] [Full Text] [Related]
43. Hemophilia A: Emicizumab monitoring and impact on coagulation testing. Nardi MA Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648 [TBL] [Abstract][Full Text] [Related]
44. [Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab]. Shutov SA; Zozulya NI; Novikov VA; Shutova NA; Glebova AI; Kitsenko EA Khirurgiia (Mosk); 2023; (5):72-83. PubMed ID: 37186654 [TBL] [Abstract][Full Text] [Related]
45. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Kitazawa T; Shima M Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119 [TBL] [Abstract][Full Text] [Related]
46. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A. Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492 [TBL] [Abstract][Full Text] [Related]
47. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study. Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431 [TBL] [Abstract][Full Text] [Related]
48. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A. Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119 [TBL] [Abstract][Full Text] [Related]
49. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A. Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547 [TBL] [Abstract][Full Text] [Related]
50. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287 [TBL] [Abstract][Full Text] [Related]
51. Laboratory issues in gene therapy and emicizumab. Bowyer AE; Lowe AE; Tiefenbacher S Haemophilia; 2021 Feb; 27 Suppl 3():142-147. PubMed ID: 32469128 [TBL] [Abstract][Full Text] [Related]
52. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559 [TBL] [Abstract][Full Text] [Related]
53. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions. Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155 [TBL] [Abstract][Full Text] [Related]
54. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions. Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318 [TBL] [Abstract][Full Text] [Related]
55. Emicizumab-kxwh: First Global Approval. Scott LJ; Kim ES Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074 [TBL] [Abstract][Full Text] [Related]
56. Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Krumb E; Fijnvandraat K; Makris M; Peyvandi F; Ryan A; Athanasopoulos A; Hermans C Haemophilia; 2021 Sep; 27(5):736-743. PubMed ID: 34191397 [TBL] [Abstract][Full Text] [Related]
57. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab. Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978 [TBL] [Abstract][Full Text] [Related]
58. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals). Nougier C; Jeanpierre E; Ternisien C; Proulle V; Hezard N; Pouplard C; Lasne D; Eur J Haematol; 2020 Dec; 105(6):675-681. PubMed ID: 32668090 [TBL] [Abstract][Full Text] [Related]
59. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759 [TBL] [Abstract][Full Text] [Related]